Observational studyMedicine2017
Analysis of early death in newly diagnosed acute promyelocytic leukemia patients.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Predictors of Early Death in Acute Promyelocytic Leukemia.Medical sciences (Basel, Switzerland) · 2025Review
- Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU.Scientific reports · 2024Article
- Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia.Journal of thrombosis and haemostasis : JTH · 2024Article
- Dysregulated hemostasis in acute promyelocytic leukemia.International journal of hematology · 2024Review
- Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy.Frontiers in oncology · 2024Article
- Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia.medRxiv : the preprint server for health sciences · 2023Article
- Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia.Blood advances · 2023Article
- Review
- Simplified predictive scores for thrombosis and bleeding complications in newly diagnosed acute leukemia patients.Thrombosis journal · 2023Article
- The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.Annals of hematology · 2022Article
- Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia.Frontiers in oncology · 2022Article
- Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?Frontiers in medicine · 2021Review
- Article
- Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia:International journal of hematology-oncology and stem cell research · 2020Review
- Whole exome sequencing detects CHST3 mutation in patient with acute promyelocytic leukemia: A case report.Medicine · 2018Article
- Are delays in diagnosis and treatment of acute leukemia in a middle-income country associated with poor outcomes? A retrospective cohort study.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients.Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatment at least 3 days after commencement (ED after treatment), low/intermediate risk, and high-risk groups.White blood cell (WBC) count, high-risk cases, prothrombin time (PT) prolongation, international society on thrombosis and hemostasis (ISTH) scores (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were higher in iED group than ED after treatment. And the time from onset to initial hospitalization or death was significantly shorter (P < .05) in iED patients. LDH level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 bleeding (P = .049) were higher in high-risk group than in ED and low/intermediate-risk groups, while the times from onset to the initial hospitalization or death were lower for ED patients in high-risk group (P = .037).We found that different types of EDs have different clinical features. A high WBC count contributes to the occurrence of more ED, which is usually not associated with delay of diagnosis and hospitalization. Current therapeutic strategies to reduce the incidence of ED in these cases are not adequate and will benefit from focused research attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.